Critical Review: Evogene (NASDAQ:EVGN) versus Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Institutional & Insider Ownership

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Coya Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Coya Therapeutics and Evogene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coya Therapeutics -643.44% -71.48% -63.57%
Evogene -694.18% -156.53% -86.80%

Analyst Recommendations

This is a summary of current ratings and price targets for Coya Therapeutics and Evogene, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics 1 0 5 0 2.67
Evogene 1 0 0 0 1.00

Coya Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 400.00%. Given Coya Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Coya Therapeutics is more favorable than Evogene.

Valuation & Earnings

This table compares Coya Therapeutics and Evogene”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coya Therapeutics $7.95 million 8.85 -$21.23 million ($1.39) -2.16
Evogene $3.85 million 0.89 -$8.48 million ($0.91) -0.43

Evogene has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Summary

Coya Therapeutics beats Evogene on 9 of the 13 factors compared between the two stocks.

About Coya Therapeutics

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

About Evogene

(Get Free Report)

Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.